GRAMD4 antibody (full length)

Catalog No. ABIN7878318

The Mouse Monoclonal anti-GRAMD4 antibody is suitable to detect GRAMD4 in samples from Human. It has been validated for FACS and IF.

Quick Overview for GRAMD4 antibody (full length) (ABIN7878318)

Target: GRAMD4 (GRAM Domain Containing 4 (GRAMD4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This GRAMD4 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Grade: Carrier-free

Clone: PCRP-GRAMD4-1A10

Product Details anti-GRAMD4 Antibody

Binding Specificity: full length

Purpose: GRAMD4 Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human GRAMD4 protein was used as the immunogen for the GRAMD4 antibody.

Isotype: IgG1

Application Details

Application Notes: Optimal dilution of the GRAMD4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Aliquot the GRAMD4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for GRAMD4

Target: GRAMD4 (GRAM Domain Containing 4 (GRAMD4))

Alternative Name: GRAMD4

Background: The gene encoding GRAMD4 (GRAM domain-containing protein 4) maps to human chromosome 22, which houses over 500 genes and is the second smallest human chromosome. GRAMD4, also designated death-inducing protein (DIP), is a 578 amino acid mitochondrial membrane protein that acts as an essential mediator of the p53-independent E2F-1 death pathway, which is frequently found to be deregulated in several types of cancers. Overexpression of GRAMD4 results in a strong apoptotic response involving caspase-3 activation and cleavage of poly(ADP-ribose)-polymerase. GRAMD4 is expressed in lung and in primary lung squamous cell carcinoma (LSCC) and shows upregulation in mitochondria by E2F1 after addition of 4-hydroxytamoxifen. This evidence suggests that GRAMD4 may be a potential target for cancer therapies.

UniProt: Q6IC98